More growth, less risk. The joint venture announced on Tuesday between the UK's biggest drugmaker and Shenzhen Neptunus, a Chinese vaccine maker, bears all the hallmarks of GlaxoSmithKline's push to diversify sales under chief executive Andrew Witty.
促进增长，降低风险。英国最大制药商葛兰素史克(GSK)与manbetx3.0 疫苗生产商深圳海王(Shenzhen Neptunus)周二宣布组建的合资企业，带有GSK在首席执行官安德鲁•威蒂(Andrew Witty)领导下推行销售多样化的一切特征。
您已阅读15%（367字），剩余85%（2120字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。